ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Receivables
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Receivables of -$31.04 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2018-08-02
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2018-06-30 was -$47.81M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2018-03-31 was $16.77M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2017-12-31 was $19.36M, a 136.42% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2017-09-30 was -$761.00K, a 113.51% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2017 was $10.67M, a 29.05% decline from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2016 was $15.04M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2015 was -$31.64M, a 188.65% decline from fiscal 2014.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2014 was $35.69M, a 761.22% increase from fiscal 2013.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$47.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$31.04M 10-Q · filed 2018-08-02 | -$11.68M derived: sum of 3 quarters · filed 2018-08-02 | -$12.44M derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | $16.77M 10-Q · filed 2018-05-04 | $36.12M derived: sum of 2 quarters · filed 2018-05-04 | $35.36M derived: sum of 3 quarters · filed 2018-05-04 | $31.31M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-12-31 | $19.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $18.60M derived: sum of 2 quarters · filed 2018-02-15 | $14.54M derived: sum of 3 quarters · filed 2018-08-02 | $10.67M 10-K · filed 2018-02-15 |
| 2017-09-30 | -$761.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$4.81M derived: sum of 2 quarters · filed 2018-08-02 | -$8.69M 10-Q · filed 2017-11-07 | -$502.00K derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-06-30 | -$4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$7.93M 10-Q · filed 2018-08-02 | $259.00K derived: sum of 3 quarters · filed 2018-08-02 | $5.89M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | -$3.88M 10-Q · filed 2018-05-04 | $4.31M derived: sum of 2 quarters · filed 2018-05-04 | $9.94M derived: sum of 3 quarters · filed 2018-05-04 | $10.64M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $8.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $13.82M derived: sum of 2 quarters · filed 2018-02-15 | $14.52M derived: sum of 3 quarters · filed 2018-02-15 | $15.04M 10-K · filed 2018-02-15 |
| 2016-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $6.33M derived: sum of 2 quarters · filed 2017-11-07 | $6.85M 10-Q · filed 2017-11-07 | $7.02M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.22M 10-Q · filed 2017-08-09 | $1.38M derived: sum of 3 quarters · filed 2018-02-15 | $111.00K derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $516.00K 10-Q · filed 2017-05-05 | $684.00K derived: sum of 2 quarters · filed 2018-02-15 | -$589.00K derived: sum of 3 quarters · filed 2018-02-15 | -$1.29M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$1.10M derived: sum of 2 quarters · filed 2018-02-15 | -$1.81M derived: sum of 3 quarters · filed 2018-02-15 | -$31.64M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$1.98M derived: sum of 2 quarters · filed 2016-11-03 | -$31.81M 10-Q · filed 2016-11-03 | $7.75M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | -$704.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$30.53M 10-Q · filed 2016-08-04 | $9.02M derived: sum of 3 quarters · filed 2017-02-15 | $9.31M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | -$29.83M 10-Q · filed 2016-05-04 | $9.72M derived: sum of 2 quarters · filed 2017-02-15 | $10.02M derived: sum of 3 quarters · filed 2017-02-15 | $9.94M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $39.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $39.85M derived: sum of 2 quarters · filed 2017-02-15 | $39.77M derived: sum of 3 quarters · filed 2017-02-15 | $35.69M 10-K · filed 2017-02-15 |
| 2014-09-30 | $295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $220.00K derived: sum of 2 quarters · filed 2015-11-09 | -$3.86M 10-Q · filed 2015-11-09 | -$225.00K derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$4.16M 10-Q · filed 2015-08-07 | -$520.00K derived: sum of 3 quarters · filed 2016-02-12 | -$371.00K derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | -$4.08M 10-Q · filed 2015-05-08 | -$445.00K derived: sum of 2 quarters · filed 2016-02-12 | -$296.00K derived: sum of 3 quarters · filed 2016-02-12 | -$394.00K derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $3.79M derived: sum of 2 quarters · filed 2016-02-12 | $3.69M derived: sum of 3 quarters · filed 2016-02-12 | $4.14M 10-K · filed 2016-02-12 |
| 2013-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $51.00K derived: sum of 2 quarters · filed 2014-11-06 | $505.00K 10-Q · filed 2014-11-06 | -$1.31M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $356.00K 10-Q · filed 2014-08-08 | -$1.46M derived: sum of 3 quarters · filed 2015-02-13 | -$3.92M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $454.00K 10-Q · filed 2014-05-09 | -$1.36M derived: sum of 2 quarters · filed 2015-02-13 | -$3.83M derived: sum of 3 quarters · filed 2015-02-13 | -$1.63M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$4.28M derived: sum of 2 quarters · filed 2015-02-13 | -$2.09M derived: sum of 3 quarters · filed 2015-02-13 | -$1.36M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$274.00K derived: sum of 2 quarters · filed 2013-11-07 | $450.00K 10-Q · filed 2013-11-07 | -$109.00K derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $2.92M 10-Q · filed 2013-08-09 | $2.36M derived: sum of 3 quarters · filed 2014-02-20 | $3.08M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $724.00K 10-Q · filed 2013-05-07 | $165.00K derived: sum of 2 quarters · filed 2014-02-20 | $884.00K derived: sum of 3 quarters · filed 2014-02-20 | $1.04M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | -$559.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $160.00K derived: sum of 2 quarters · filed 2014-02-20 | $318.00K derived: sum of 3 quarters · filed 2014-02-20 | -$1.98M 10-K · filed 2014-02-20 |
| 2011-09-30 | $719.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $877.00K derived: sum of 2 quarters · filed 2012-11-05 | -$1.42M 10-Q · filed 2012-11-05 | -$2.85M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$2.14M 10-Q · filed 2012-08-08 | -$3.57M derived: sum of 3 quarters · filed 2013-02-19 | -$5.05M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | -$2.30M 10-Q · filed 2012-05-03 | -$3.73M derived: sum of 2 quarters · filed 2013-02-19 | -$5.21M derived: sum of 3 quarters · filed 2013-02-19 | -$3.35M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | -$2.91M derived: sum of 2 quarters · filed 2013-02-19 | -$1.05M derived: sum of 3 quarters · filed 2013-02-19 | -$2.59M 10-K · filed 2013-02-19 |
| 2010-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $376.00K derived: sum of 2 quarters · filed 2011-11-03 | -$1.16M 10-Q · filed 2011-11-03 | -$141.00K derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | $314.00K 10-Q · filed 2011-08-03 | $1.34M derived: sum of 3 quarters · filed 2012-02-13 | $501.00K derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | -$1.54M 10-Q · filed 2011-05-05 | -$517.00K derived: sum of 2 quarters · filed 2012-02-13 | -$1.35M derived: sum of 3 quarters · filed 2012-02-13 | |
| 2009-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | $187.00K derived: sum of 2 quarters · filed 2012-02-13 | $1.86M 10-K · filed 2012-02-13 | |
| 2009-09-30 | -$835.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | $834.00K 10-Q · filed 2010-11-04 | ||
| 2009-06-30 | $1.67M 10-Q · filed 2010-08-05 | |||
| 2008-12-31 | -$843.00K 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |